2026 Global: Alzheimer'S Disease Diagnostic Market -Competitive Review (2032) report
Description
The 2026 Global: Alzheimer'S Disease Diagnostic Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for alzheimer's disease diagnostic market by geography and historical trend. The scope of the report extends to sizing of the alzheimer's disease diagnostic market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
F. Hoffmann‑La Roche (Roche) is a leading player in Alzheimer’s diagnostics through its development of plasma pTau assays and partnerships to commercialize blood‑based biomarkers that aim to broaden access to early detection, with Roche’s pTau217 assay receiving regulatory attention and collaborative validation in clinical studies. Quanterix specializes in ultra‑sensitive immunoassay platforms (SIMOA) that quantify Alzheimer’s biomarkers such as neurofilament light (NfL) and phosphorylated tau in blood and CSF, enabling research and clinical laboratories to detect pathological changes earlier and with greater analytic sensitivity than conventional assays. Fujirebio has advanced immunoassays and was part of the first FDA‑cleared blood test (Lumipulse G pTau217/β‑Amyloid 1‑42 plasma ratio) for amyloid‑related detection, positioning the company as a major IVD provider for clinicians seeking scalable, lab‑based diagnostic options. ALZpath has emerged as an influential innovator with its proprietary pTau217 antibody used in several high‑performance blood tests and with recognition for accelerating commercialization of pTau‑based assays through licensing and partnerships with large diagnostics firms.
Quest Diagnostics, a global clinical laboratory company, offers centralized blood testing services for Alzheimer’s biomarkers and recently launched blood tests intended to support amyloid pathology confirmation in patients with mild cognitive impairment or dementia, leveraging its large network to expand clinical availability. Siemens Healthineers and GE HealthCare provide imaging systems, AI‑enabled analysis, and diagnostic workflows that support PET and MRI imaging for amyloid and tau pathology assessment, integrating hardware and software to improve diagnostic throughput in hospital and imaging‑center settings. Lantheus is developing F‑18 PET radiotracers (including tau tracers such as MK‑6240) that enhance molecular imaging specificity for tau pathology, bolstering nuclear medicine’s role in differential diagnosis and staging of Alzheimer’s disease. C2N Diagnostics (now part of collaborative networks) and Labcorp supply laboratory testing services and biomarker assays used in clinical trials and diagnostic pathways, supporting sample acquisition, high‑throughput testing, and validation studies that underpin clinical adoption of novel biomarkers.
Smaller but strategically important firms include Beckman Coulter (bioMérieux/Beckman collaborations) and Biotechne (and partners such as Alamar Biosciences), which supply reagents, assay platforms, and validated antibodies that underpin many research and diagnostic tests for phosphorylated tau and amyloid peptides, enabling assay standardization and scale‑up across clinical labs. Startups and biotech innovators—examples such as ALZpath, Treventis, and other specialized diagnostic developers—contribute cutting‑edge pTau assays, novel biomarkers, and AI cognitive assessment tools that together drive rapid evolution of the diagnostic ecosystem by improving sensitivity, lowering cost, and expanding settings of care from specialty centers to community clinics.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for alzheimer's disease diagnostic market by geography and historical trend. The scope of the report extends to sizing of the alzheimer's disease diagnostic market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
F. Hoffmann‑La Roche (Roche) is a leading player in Alzheimer’s diagnostics through its development of plasma pTau assays and partnerships to commercialize blood‑based biomarkers that aim to broaden access to early detection, with Roche’s pTau217 assay receiving regulatory attention and collaborative validation in clinical studies. Quanterix specializes in ultra‑sensitive immunoassay platforms (SIMOA) that quantify Alzheimer’s biomarkers such as neurofilament light (NfL) and phosphorylated tau in blood and CSF, enabling research and clinical laboratories to detect pathological changes earlier and with greater analytic sensitivity than conventional assays. Fujirebio has advanced immunoassays and was part of the first FDA‑cleared blood test (Lumipulse G pTau217/β‑Amyloid 1‑42 plasma ratio) for amyloid‑related detection, positioning the company as a major IVD provider for clinicians seeking scalable, lab‑based diagnostic options. ALZpath has emerged as an influential innovator with its proprietary pTau217 antibody used in several high‑performance blood tests and with recognition for accelerating commercialization of pTau‑based assays through licensing and partnerships with large diagnostics firms.
Quest Diagnostics, a global clinical laboratory company, offers centralized blood testing services for Alzheimer’s biomarkers and recently launched blood tests intended to support amyloid pathology confirmation in patients with mild cognitive impairment or dementia, leveraging its large network to expand clinical availability. Siemens Healthineers and GE HealthCare provide imaging systems, AI‑enabled analysis, and diagnostic workflows that support PET and MRI imaging for amyloid and tau pathology assessment, integrating hardware and software to improve diagnostic throughput in hospital and imaging‑center settings. Lantheus is developing F‑18 PET radiotracers (including tau tracers such as MK‑6240) that enhance molecular imaging specificity for tau pathology, bolstering nuclear medicine’s role in differential diagnosis and staging of Alzheimer’s disease. C2N Diagnostics (now part of collaborative networks) and Labcorp supply laboratory testing services and biomarker assays used in clinical trials and diagnostic pathways, supporting sample acquisition, high‑throughput testing, and validation studies that underpin clinical adoption of novel biomarkers.
Smaller but strategically important firms include Beckman Coulter (bioMérieux/Beckman collaborations) and Biotechne (and partners such as Alamar Biosciences), which supply reagents, assay platforms, and validated antibodies that underpin many research and diagnostic tests for phosphorylated tau and amyloid peptides, enabling assay standardization and scale‑up across clinical labs. Startups and biotech innovators—examples such as ALZpath, Treventis, and other specialized diagnostic developers—contribute cutting‑edge pTau assays, novel biomarkers, and AI cognitive assessment tools that together drive rapid evolution of the diagnostic ecosystem by improving sensitivity, lowering cost, and expanding settings of care from specialty centers to community clinics.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
